All In Biotech

Drug Trial Radar · NCT06384807

A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

A Phase 1/2, First in Human, Dose Escalation and Dose Expansion Study of BHV-1510 (Previously PBI-410) as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Apr 22, 2024

Primary completion

Feb 2028

Study completion Feb 2028

Sponsor

Lead sponsor
Biohaven Therapeutics Ltd.Industry
Sponsor type
Industry
First posted
Apr 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors.

Conditions

  • Solid Tumor

Interventions

  • BHV-1510Drug

    BHV-1510 will be administered on Day 1 every 3 weeks

  • CemiplimabDrug

    cemiplimab (350mg) will be administered as an IV infusion on Day 1 every 3 weeks

  • BHV-1510Drug

    BHV-1510 will be administered on Day 1 every 2 weeks

  • BHV-1510Drug

    BHV-1510 will be administered on Day 1 and Day 8 every 3 weeks

  • CemiplimabDrug

    cemiplimab (350mg) will be administered as an IV infusion on Day 1 and Day 8 every 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Number of patients with adverse events (AEs)Time frame: Through study completion, estimated as an average of 47 months
  2. Phase 1: Recommended doses or schedules for expansion (RDEs) and maximum tolerated dose (MTD)Time frame: Approximately 15 months
  3. Phase 2: Objective Response Rate (ORR) for BHV-1510 for monotherapy and in combination with cemiplimabTime frame: Through study completion, estimated as an average of 47 months
  4. Phase 2: Number of patients with AEs for BHV-1510 for monotherapy and in combination with cemiplimabTime frame: Through study completion, estimated as an average of 47 months
  5. Phase 2: Duration of Response (DoR) for BHV-1510 for monotherapy and in combination with cemiplimabTime frame: Through study completion, estimated as an average of 47 months

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Site-113

    Duarte, California · Recruiting

  • Site-112

    La Jolla, California · Recruiting

  • Site-111

    Palo Alto, California · Recruiting

  • Site-114

    Washington D.C., District of Columbia · Recruiting

  • Site-103

    Miami, Florida · Recruiting

  • Site-105

    Orlando, Florida · Recruiting

  • Site-115

    Tampa, Florida · Recruiting

  • Site-110

    Augusta, Georgia · Recruiting

  • Site-109

    Detroit, Michigan · Recruiting

  • Site-101

    St Louis, Missouri · Completed

  • Site-117

    New York, New York · Recruiting

  • Site-116

    Oklahoma City, Oklahoma · Recruiting

  • Site-108

    Philadelphia, Pennsylvania · Recruiting

  • Site-107

    Nashville, Tennessee · Recruiting

  • Site-104

    Dallas, Texas · Recruiting

  • Site-106

    West Valley City, Utah · Recruiting

  • Site-102

    Fairfax, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.